Logo-jre
Submitted: 11 Sep 2020
Accepted: 10 Oct 2020
ePublished: 20 Nov 2020
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

J Renal Endocrinol. 2021;7(1): e09.
  Abstract View: 173
  PDF Download: 69

Original Article

Cholecalciferol therapy; is it the gold standard for vitamin D deficiency and mineral disorders in hemodialysis?

Mouna Jerbi 1 * , Hiba Ghabi 2, Hanene Gaied 2, Fathi Ben Hmida 3, Raja Aoudia 3, Rim Goucha 1, Taieb Ben Abdallah 3

1 Department of Nephrology, Mongi Slim Hospital, Marsa, Laboratory of Kidney Pathology (LR00SP01) Charles Nicolle Hospital, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.
2 La Rabta Hospital, Department of Nephrology, Faculty of Medicine Tunis, University of Tunis El Manar, Tunis, Tunisia.
3 Department of Nephrology, Charles Nicolle Hospital, Laboratory of Kidney Pathology (LR00SP01) Charles Nicolle Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia.
*Corresponding Author: Mouna Jerbi, Email: mounaeleuch@outlook.fr

Abstract

Introduction: Vitamin D deficiency is frequently observed among dialysis patients. Previous studies suggested that 50 to 90% of end-stage renal disease patients are deficient in vitamin D. In Tunisia, studies regarding hypovitaminosis D in patients on dialysis are not numerous. Actually, many data support the use of native vitamin D in hemodialysis (HD) patients. In Tunisia, using native vitamin D is not part of therapeutic habits of all dialysis centers.

Objectives: The aim of this study was to determine the prevalence of vitamin D deficiency in patients with chronic kidney disease stage 5 undergoing HD and to evaluate the effect of oral cholecalciferol supplementation, in intact parathormone (iPTH), serum calcium and serum phosphorus.

Patients and Methods: We conducted a pre-experimental study among HD patients. Monthly oral supplementation with Cholecalciferol, was instituted for six months.

Results: Forty-three participants were included. The mean 25-hydroxy vitamin D concentration was 17.89 ng/mL. Vitamin D deficiency was observed in 83.7% of our patients. We observed a significant increase in 25-hydroxy vitamin D and calcium levels and a significant decline in iPTH levels. No evidence of toxicity, nor severe hypercalcemia or hyperphosphatemia was noted.

Conclusion: The supplementation with cholecalciferol seems reasonable and well tolerated in HD patients if reasonable doses are used with regular monitoring.

Keywords: Vitamin D, Hemodialysis, Chronic kidney disease, Hemodialysis, Parathormone, End-stage renal disease
First Name
 
Last Name
 
Email Address
 
Comments
 
Security code


Abstract View: 173

Your browser does not support the canvas element.


PDF Download: 69

Your browser does not support the canvas element.